En els darrers anys, la immunoter\u00e0pia s’ha consolidat com una de les noves i principals esperances en la lluita contra el c\u00e0ncer. Aquesta aproximaci\u00f3 terap\u00e8utica es basa en el fet que el nostre sistema immunitari est\u00e0 constantment vigilant l’aparici\u00f3 de pres\u00e8ncies estranyes dins l\u2019organisme i combatent-les. Quan s\u2019origina un tumor, les seves mutacions converteixen les c\u00e8l\u00b7lules canceroses en elements sensiblement diferents a la resta de les nostres c\u00e8l\u00b7lules, i, gr\u00e0cies a aquesta singularitat, les defenses lluiten per eliminar-lo. Per\u00f2 aquesta estrat\u00e8gia natural acostuma a fracassar perqu\u00e8 el c\u00e0ncer troba camins per deslliurar-se\u2019n i, aix\u00ed, progressar.<\/p>\n
\u00a0<\/p>\n
Una de les vies d\u2019escapament que desenvolupen els tumors per evitar el control immunitari consisteix en cobrir-se d’una mena de capa d’invisibilitat<\/strong>. Per a fer-ho tenen a la seva superf\u00edcie mol\u00e8cules com l’anomenada PD-L1. En concret, la interacci\u00f3 entre PD-L1 i PD-1 (que n\u2019\u00e9s complement\u00e0ria) atenua la resposta immunit\u00e0ria perqu\u00e8 inhibeix la proliferaci\u00f3 i la funci\u00f3 de les c\u00e8l\u00b7lules T del sistema immunol\u00f2gic. O, dit d\u2019una altra manera, l\u2019increment anormal de l\u2019expressi\u00f3 de controladors negatius de la resposta immunit\u00e0ria (com el nivells elevats del lligand PD-L1) contribueix en la toler\u00e0ncia immune del nostre organisme davant de les c\u00e8l\u00b7lules tumorals. Per aquest motiu, el bloqueig del punt de control immunol\u00f2gic corresponent a la interacci\u00f3 de PD-L1 amb PD-1 ja \u00e9s, avui dia, una estrat\u00e8gia terap\u00e8utica que s\u2019aplica en diversos tipus de tumors (s\u00f3n les anomenades ter\u00e0pies anti-PD-1\/-PD-L1).<\/p>\n \u00a0<\/p>\n El treball recent que ha publicat el grup de la Dra. Montse S\u00e1nchez-C\u00e9spedes, cap del grup de gens i c\u00e0ncer del programa d\u2019Epigen\u00e8tica i Biologia del C\u00e0ncer (PEBC) de l\u2019IDIBELL, fa un pas m\u00e9s en la descripci\u00f3 i comprensi\u00f3 de les bases gen\u00e8tiques que atorguen a les c\u00e8l\u00b7lules tumorals de pulm\u00f3 la capacitat d\u2019escapar dels punts de control de la immunovigil\u00e0ncia.<\/p>\n \u00a0<\/p>\n En concret, els resultats recentment publicats demostren, per una banda, que l\u2019activaci\u00f3 de l\u2019oncogen MET augmenta l\u2019expressi\u00f3 de reguladors negatius dels punts de control de la resposta immunit\u00e0ria, com PD-L1. Per l\u2019altra, tamb\u00e9 es demostra que la inactivaci\u00f3 de JAK2, mitjan\u00e7ant mutacions o delecions del gen, compromet la resposta a l\u2019interfer\u00f3. Aquestes dues alteracions, doncs, faciliten el creixement tumoral habilitant la toler\u00e0ncia immunit\u00e0ria i afecten, per tant, la resposta de les c\u00e8l\u00b7lules als inhibidors dels punts de control immunol\u00f2gic, tot esdevenint marcadors de resist\u00e8ncia a la immunoter\u00e0pia.<\/p>\n \u00a0<\/p>\n Per assolir aquests resultats, l\u2019equip de recerca ha comptat amb remarcables contribucions d\u2019investigadors de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) de l\u2019Hospitalet, del programa Oncobell de l\u2019IDIBELL, de l\u2019Hospital Universitari de Bellvitge, del Centre Nacional d\u2019An\u00e0lisi Gen\u00f2mica (CNAG-CRG) i del Centre Hospitalier Universitaire de Grenoble.<\/p>\n","protected":false},"excerpt":{"rendered":" En els darrers anys, la immunoter\u00e0pia s’ha consolidat com una de les noves i principals esperances en la lluita contra el c\u00e0ncer. Aquesta aproximaci\u00f3 terap\u00e8utica es basa en el fet que el nostre sistema immunitari est\u00e0 constantment vigilant l’aparici\u00f3 de pres\u00e8ncies estranyes dins l\u2019organisme i combatent-les. Quan s\u2019origina un tumor, les seves mutacions converteixen les […]<\/p>\n","protected":false},"author":6,"featured_media":10571,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,376],"tags":[],"class_list":["post-7625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-epigenetica-del-cancer"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 00:53:37","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7625"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10571"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}